Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: Access to Medicines
Updated TRIPS Flexibilities Database
Ellen 't Hoen
-
April 17, 2023
New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
Kaitlin Mara
-
April 12, 2023
Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the...
Ellen 't Hoen
-
March 16, 2023
Right to breathe takes precedence over company profits: Families of cystic...
Kaitlin Mara
-
February 28, 2023
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero...
Ellen 't Hoen
-
February 28, 2023
Medicines price transparency: Ground still left to cover
Katrina Perehudoff
-
February 3, 2023
Wrapping up 2022 with some noteworthy medicines, law and policy events
Medicines Law & Policy
-
December 22, 2022
Seven recommendations for sharing intellectual property, know-how and technology – report...
Medicines Law & Policy
-
July 18, 2022
Some Surprises in the European Commission’s New Intellectual Property Strategy
Ellen 't Hoen
-
December 2, 2020
Remdesivir developed country price announced
Ellen 't Hoen
-
June 30, 2020
1
2
3
4
Page 1 of 4
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok